Loading...

Sunil Advani

TitleAssociate Professor In Residence
InstitutionUniversity of California San Diego
DepartmentRadiation Medicine and Applied Science
Address9500 Gilman Drive #0861
La Jolla CA 92093
Phone858-822-7574
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Elucidation and therapeutic exploitation of PAK mediated radioresistance
    NIH/NCI R01CA215081Dec 18, 2017 - Nov 30, 2022
    Role: Principal Investigator
    Developing targeted activatable peptides to amplify radiosensitizer delivery
    NIH/NCI R03CA219744Aug 15, 2017 - Jul 31, 2019
    Role: Principal Investigator
    Restricting radiosensitization through ErbB targeted antibody drug conjugates
    NIH/NCI R21CA205765Apr 1, 2016 - Mar 31, 2018
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Cerviño L, Soultan D, Cornell M, Yock A, Pettersson N, Song WY, Aguilera J, Advani S, Murphy J, Hoh C, James C, Paravati A, Coope R, Gill B, Moiseenko V. A novel 3D-printed phantom insert for 4D PET/CT imaging and simultaneous integrated boost radiotherapy. Med Phys. 2017 Oct; 44(10):5467-5474. PMID: 28766726.
      View in: PubMed
    2. Mell LK, Brumund KT, Daniels GA, Advani S, Zakeri K, Wright ME, Onyeama SJ, Weisman RA, Sanghvi PR, Martin PJ, Szalay AA. Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma. Clin Cancer Res. 2017 Oct 01; 23(19):5696-5702. PMID: 28679776.
      View in: PubMed
    3. Wilson R, Espinosa-Diez C, Kanner N, Chatterjee N, Ruhl R, Hipfinger C, Advani S, Li J, Khan OF, Franovic A, Weis SM, Kumar S, Coussens LM, Anderson DG, Chen CC, Cheresh DA, Anand S. MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment. Nat Commun. 2016 Nov 25; 7:13597. PMID: 27886180.
      View in: PubMed
    4. Adams SR, Yang HC, Savariar EN, Aguilera J, Crisp JL, Jones KA, Whitney MA, Lippman SM, Cohen EE, Tsien RY, Advani S. Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. Nat Commun. 2016 Oct 04; 7:13019. PMID: 27698471.
      View in: PubMed
    5. Yu V, Rahimy M, Korrapati A, Xuan Y, Zou AE, Krishnan AR, Tsui T, Aguilera JA, Advani S, Crotty Alexander LE, Brumund KT, Wang-Rodriguez J, Ongkeko WM. Electronic cigarettes induce DNA strand breaks and cell death independently of nicotine in cell lines. Oral Oncol. 2016 Jan; 52:58-65. PMID: 26547127; PMCID: PMC4891196 [Available on 01/01/17].
    6. Advani S, Camargo MF, Seguin L, Mielgo A, Anand S, Hicks AM, Aguilera J, Franovic A, Weis SM, Cheresh DA. Kinase-independent role for CRAF-driving tumour radioresistance via CHK2. Nat Commun. 2015 Sep 03; 6:8154. PMID: 26333361; PMCID: PMC4559870.
    7. Paravati AJ, Hawkins PG, Martin AN, Mansy G, Rahn DA, Advani S, Hoisak J, Dragojevic I, Martin PJ, Miller CJ, Sanghvi P. Clinical and cosmetic outcomes in patients treated with high-dose-rate electronic brachytherapy for nonmelanoma skin cancer. Pract Radiat Oncol. 2015 Nov-Dec; 5(6):e659-64. PMID: 26432680.
      View in: PubMed
    8. Raju SC, Hauff SJ, Lemieux AJ, Orosco RK, Gross AM, Nguyen LT, Savariar E, Moss W, Whitney M, Cohen EE, Lippman SM, Tsien RY, Ideker T, Advani S, Nguyen QT. Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metalloproteinase activity in head and neck carcinoma. Oral Oncol. 2015 May; 51(5):470-5. PMID: 25735654; PMCID: PMC4427339.
    9. Buckel L, Savariar EN, Crisp JL, Jones KA, Hicks AM, Scanderbeg DJ, Nguyen QT, Sicklick JK, Lowy AM, Tsien RY, Advani S. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 01; 75(7):1376-1387. PMID: 25681274; PMCID: PMC4458508.
    10. Buckel L, Advani S, Frentzen A, Zhang Q, Yu YA, Chen NG, Ehrig K, Stritzker J, Mundt AJ, Szalay AA. Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium. Int J Cancer. 2013 Dec 15; 133(12):2989-99. PMID: 23729266.
      View in: PubMed
    11. Advani S, Buckel L, Chen NG, Scanderbeg DJ, Geissinger U, Zhang Q, Yu YA, Aguilar RJ, Mundt AJ, Szalay AA. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts. Clin Cancer Res. 2012 May 01; 18(9):2579-90. PMID: 22379115.
      View in: PubMed
    12. Mielgo A, Seguin L, Huang M, Camargo MF, Anand S, Franovic A, Weis SM, Advani S, Murphy EA, Cheresh DA. A MEK-independent role for CRAF in mitosis and tumor progression. Nat Med. 2011 Nov 13; 17(12):1641-5. PMID: 22081024; PMCID: PMC3233644.
    13. Kesari S, Advani S, Lawson JD, Kahle KT, Ng K, Carter B, Chen CC. DNA damage response and repair: insights into strategies for radiation sensitization of gliomas. Future Oncol. 2011 Nov; 7(11):1335-46. PMID: 22044206; PMCID: PMC3236247.
    14. Advani S, Markert JM, Sood RF, Samuel S, Gillespie GY, Shao MY, Roizman B, Weichselbaum RR. Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. Gene Ther. 2011 Nov; 18(11):1098-102. PMID: 21544094.
      View in: PubMed
    15. Advani S, Weichselbaum RR, Chmura SJ. Enhancing radiotherapy with genetically engineered viruses. J Clin Oncol. 2007 Sep 10; 25(26):4090-5. PMID: 17827458.
      View in: PubMed
    16. Advani S, Mezhir JJ, Roizman B, Weichselbaum RR. ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):637-46. PMID: 17011442.
      View in: PubMed
    17. Mezhir JJ, Advani S, Smith KD, Darga TE, Poon AP, Schmidt H, Posner MC, Roizman B, Weichselbaum RR. Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses. Cancer Res. 2005 Oct 15; 65(20):9479-84. PMID: 16230412.
      View in: PubMed
    18. Durand LO, Advani S, Poon AP, Roizman B. The carboxyl-terminal domain of RNA polymerase II is phosphorylated by a complex containing cdk9 and infected-cell protein 22 of herpes simplex virus 1. J Virol. 2005 Jun; 79(11):6757-62. PMID: 15890914; PMCID: PMC1112163.
    19. Advani S, Durand LO, Weichselbaum RR, Roizman B. Oct-1 is posttranslationally modified and exhibits reduced capacity to bind cognate sites at late times after infection with herpes simplex virus 1. J Virol. 2003 Nov; 77(22):11927-32. PMID: 14581529; PMCID: PMC254286.
    20. Curi MA, Skelly CL, Meyerson SL, Baldwin ZK, Balasubramanian V, Advani S, Glagov S, Roizman B, Weichselbaum RR, Schwartz LB. Sustained inhibition of experimental neointimal hyperplasia with a genetically modified herpes simplex virus. J Vasc Surg. 2003 Jun; 37(6):1294-300. PMID: 12764278.
      View in: PubMed
    21. Advani S, Weichselbaum RR, Roizman B. Herpes simplex virus 1 activates cdc2 to recruit topoisomerase II alpha for post-DNA synthesis expression of late genes. Proc Natl Acad Sci U S A. 2003 Apr 15; 100(8):4825-30. PMID: 12665617; PMCID: PMC153640.